Investor Relations

Investor Relations

Cyxone is a Swedish biotech company that develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis in convenient administration forms.

With two unique projects, both developing towards important and potentially value-creating milestones, Cyxone is well positioned to deliver consequential benefits for patients, the health care system as well as for its shareholders. Cyxone’s goal is to out-license projects to strong partners after Phase 2 clinical trials to maximize their potential.

Cyxone’s financial statements are prepared in accordance with International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (IASB) as adopted by the EU.

Download Cyxone’s Significant Accounting Principles as PDF

Investor Relations contact
Carl-Magnus Högerkorp, interim CEO
carl.hogerkorp@cyxone.com

Latest Press Release

  • Cyxone receive regulatory approval to start clinical Phase 2b study in RA

    September 19, 2022 08:30 (CEST)

    Cyxone (publ), a biotech company in autoimmune diseases, have received approvals from the Medical Product Agency (Office for Registration of Medicinal Products, Medical devices and Biocides) and the Central Ethics Committee in Poland to start a clinical Phase 2b study with its drug candidate Rabeximod, which is being developed as a treatment for rheumatoid arthritis (RA).

    Read more

Financial Calendar

Interim Report Q3, 2022

Date: 27 October 2022

Year-end Report 2022

Date: 17 February 2023